CRISPR News and Research

Latest CRISPR News and Research

Genetically engineered mosquitoes halt Dengue spread

A new study published in the journal PLOS Pathogens in January 2020 reports the development of mosquitoes that have been genetically modified to resist infection by several types of the dengue virus. This is the first time ever that all types of the virus have been targeted by the engineering of the mosquito DNA. Covering all virus types is essential to achieve proper disease control.

16 Jan 2020

ERS Genomics signs licensing agreement with Daiichi Sankyo

ERS Genomics today announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan.

14 Jan 2020

Horizon Discovery to offer novel base editing technology for clinical research

Horizon Discovery today announced that it will provide access to a novel base editing technology licensed from Rutgers for exclusive use in therapeutic, diagnostic and services applications.

From Revvity 14 Jan 2020

Leukemic cells are addicted to vitamin B6, research shows

Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division.

13 Jan 2020

Boston researchers develop novel approach to generate intestinal organoids in vitro

Boston researchers have developed a new way to generate groups of intestinal cells that can be used, among others, to make disease models in the lab to test treatments for diseases affecting the gastrointestinal system.

11 Jan 2020

Mohamad Khazaei receives SCTM’s Young Investigator Award

Mohamad Khazaei, Ph.D., scientific associate in Dr. Michael Fehlings' lab at Krembil Research Institute, Toronto, is the latest recipient of STEM CELLS Translational Medicine's (SCTM) Young Investigator Award.

9 Jan 2020

ERS Genomics and New England Biolabs sign agreement to commercialize CRISPR/Cas9 tools, reagents

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs, a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.

From New England Biolabs 9 Jan 2020

Study shows potential new approach to treating two common subtypes of lymphoma

A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein.

8 Jan 2020

The first clinical trials of CRISPR gene editing have shown promising results

Results of clinical trials testing CRISPR suggest that treating diseases with the gene-editing tool may be on the horizon.

7 Jan 2020

Using CRISPR to switch off pain gene becomes a possibility with new study

A pathbreaking study reports success in disabling an important gene that is responsible for inducing the sensation of pain.

7 Jan 2020

Prison sentences given to scientists who gene-edited babies

The three scientists responsible for the creation of three gene-edited babies have received prison sentences.

6 Jan 2020

Mount Sinai awarded more than $10 million in federal funding for research on glioblastoma

The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in federal funding for several projects focusing on brain tumor research.

2 Jan 2020

Study reveals key insight into the development of hair bundles

New research reveals a key insight into the development of hair bundles, the intricately complex assemblies in the inner ear responsible for hearing.

2 Jan 2020

Promega and MilliporeSigma sign license agreement to expand the potential of CRISPR

Promega announce license agreement with MilliporeSigma, a leader in genome editing, to access MilliporeSigma’s foundational CRISPR genome-editing technology.

From Promega Corporation 2 Jan 2020

Advancement in reconstitution of the blood system from human pluripotent stem cells

The reconstitution of the blood system in humans holds great therapeutic potential to treat many disorders, like blood cancers, sickle-cell anemia and others.

31 Dec 2019

Study uncovers key protein that supports the growth of many colorectal cancers

Researchers at the University of Toronto have identified a key protein that supports the growth of many colorectal cancers.

28 Dec 2019

Inserting end-modified DNA fragments with CRISPR-Cas9 yields highest efficiency

University of Illinois researchers achieved the highest reported rates of inserting genes into human cells with the CRISPR-Cas9 gene-editing system, a necessary step for harnessing CRISPR for clinical gene-therapy applications.

23 Dec 2019

Research shows how the hepatitis D virus copies itself

A team of researchers has discovered how one crucial step occurs in the lifecycle of the hepatitis D virus (HDV), which causes the widespread and hard to treat liver inflammation called hepatitis D. The study, which was published recently in the Journal of Virology, could help develop antiviral therapy to control this disease.

22 Dec 2019

Study uncovers a previously unknown subtype of muscle stem cells

Scientists have discovered a new subtype of muscle stem cells. These cells have the ability to build and regenerate new muscles, making them interesting targets for the development of gene therapies.

21 Dec 2019

Combined datasets can expedite the discovery and development of new cancer drugs

A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.

20 Dec 2019